Floatz logo

Trastuzumab Deruxtecan

Throat Cancer

AstraZenecaantibody_drug_conjugateActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Throat Cancer cohort.

Asset / SponsorPhaseRating
e7 tcr-t cells
Christian Hinrichs
Phase 2CCC
Cetuximab
M.D. Anderson Cancer Center
Phase 1CC
Valproic Acid
M.D. Anderson Cancer Center
Phase 1CC
Temsirolimus
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →